Features | Healtcare News | BioTuesdays by Kilmer Lucas IR

This Week's Feature

Cyclacel translating cancer biology into potential medicines

Spiro Rombotis, President and CEO Cyclacel (NASDAQ:CYCC) is developing several innovative therapies that target various phases of cell cycle control for the treatment of solid tumor and blood-borne cancers, such as...

April 13, 2021

Features

Entasis Therapeutics targeting critical pathogens with precision antibiotics

Manos Perros, Ph.D., President and CEO Entasis Therapeutics (NASDAQ:ETTX) is developing a clinical and preclinical pipeline of potential first- and best-in-class targeted antibiotics to treat serious multidrug-resistant...

April 6, 2021

Features

Varsha Rao talks up Nurx convenient and affordable care for sensitive health needs

Varsha Rao, CEO As CEO of closely-held Nurx, the leading female-focused telehealth platform offering patients transparent pricing and judgment-free care, Varsha Rao brings decades of experience balancing mission-driven...

March 30, 2021

Features

KA Imaging Reveal device a game changer in reinventing X-ray with dual energy

X-ray manufacturer, KA Imaging, is reinventing dual energy X-rays with its Reveal 35C device, which can produce three images from a single exposure, overcoming clinical and technical issues that exist with traditional X...

March 23, 2021

Features

Petros Pharma looking to pursue OTC status for its Stendra erectile dysfunction therapy

Petros Pharmaceuticals (NASDAQ:PTPI) has set up a steering committee with the aim of applying to the FDA to make its prescription erectile dysfunction (ED) therapy, Stendra, available as an over-the-counter product in a...

March 16, 2021

Features

Kezar Life Sciences harnessing master regulators of cellular functions to tackle disease

Kezar Life Sciences (NASDAQ:KZR) is advancing two drug development programs that have the potential to address a number of indications by harnessing different “master regulators” of cellular function: protein...

March 9, 2021

Features

111’s next-gen S2B2C model is transforming China’s legacy healthcare system

Junling Liu, Co-founder, Chairman and CEO Shanghai-based 111, Inc. (NASDAQ:YI) is helping pioneer the S2B2C model in China as it builds an innovative healthcare platform in the country. Unlike B2C, where businesses...

March 2, 2021

Features

Keith Sullivan discusses turnaround plan for Neuronetics

As the recently installed president and CEO of Neuronetics (NASDAQ:STIM), a commercial-stage medical device company focused on designing, developing and marketing products that improve the quality of life for patients...

February 23, 2021

Features

Achieve Life Sciences in pivotal trial with cytisinicline for new smoking cessation and nicotine addiction treatment

Achieve Life Sciences (NASDAQ:ACHV) began a pivotal trial in the fourth quarter of 2020 to evaluate cytisinicline, which is derived from the seeds of the laburnum tree, as a potential new treatment for smoking cessation...

February 16, 2021

Features

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

VistaGen Therapeutics (NASDAQ:VTGN) plans to begin a Phase 3 clinical trial in the second quarter with PH94B, a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in...

February 9, 2021

Features

ARSTAT developing portfolio of transformational products for women’s health

Closely-held ARSTAT Pharmaceuticals is advancing two patented Phase 3-ready assets: Nuvocept, the first and only oral contraceptive designed for overweight and obese women, and another contraceptive brand, Duacept, as a...

February 2, 2021

Features

Lineage Cell Therapeutics readies milestone-rich 2021 in 3 clinical programs

Lineage Cell Therapeutics (NYSE American, TASE:LCTX) expects to report important milestones in its cell therapy clinical programs in dry AMD, cervical spinal cord injury and oncology in 2021, as well as improve its...

January 26, 2021

Features

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

PDS Biotechnology (NASDAQ: PDSB) expects to report preliminary data in the first or second quarter of 2021 from a collaboration with the NCI, evaluating its lead oncology product, PDS0101, for the treatment of advanced...

January 19, 2021

Features

Tarsus Pharma developing first treatment for Demodex blepharitis, an ocular condition

Tarsus Pharmaceuticals (NASDAQ:TARS) launched the Phase 2b/3 Saturn-1 clinical trial in September 2020 with its lead asset, TP-03, as the potential first therapeutic for Demodex blepharitis, where eyelids become red...

January 12, 2021

Features

Sernova in clinical development for functional cure of Type 1 Insulin-dependent diabetes

Sernova’s (TSXV:SVA; OTCQB:SEOVF) Cell Pouch System, composed of an implantable device, therapeutic cells and immune protection technologies, has the potential to be a “functional cure” for millions of people with Type...

January 5, 2021

Features

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Closely-held Ripple Therapeutics inked a transformative strategic investment and licensing deal for its lead product candidate, IBE-814 IVT, an intravitreal implant being developed for the treatment of diabetic macular...

December 15, 2020

Features

Plus Therapeutics targeting potent radiotherapy directly against glioblastoma

Plus Therapeutics (NASDAQ:PSTV) is developing its lead asset, rhenium nanoliposome (RNL), a targeted and potentially more potent radionucleotide therapy, for the treatment of recurrent glioblastoma and several other...

December 8, 2020

Features

Genelux advancing oncolytic vaccinia virus into pivotal ovarian cancer trial in 2021

Closely-held Genelux expects to arrange an end-of-Phase 2 meeting with the FDA in the first quarter of 2021 and then launch a Phase 3 trial in mid-year with its Olvi-Vec vaccinia virus in combination with chemotherapy...

December 1, 2020

Features

Izotropic Breast CT Imaging System targeting earlier cancer detection

Izotropic (CSE:IZO; OTC:IZOZF; FSE:1R3) is developing a dedicated breast imaging system aimed at the better detection – and potentially earlier diagnosis and treatment – of breast cancer.

November 24, 2020

Features

Kintara Therapeutics readies two late-stage cancer drug candidates

Saiid Zarrabian, President and CEO Kintara Therapeutics (NASDAQ:KTRA), fresh off a merger and $25-million private placement, is moving into a global registration trial in newly-diagnosed and recurrent glioblastoma...

November 17, 2020

Features

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

After close to three decades developing its artificial intelligence platform, Hepion Pharmaceuticals (NASDAQ:HEPA) is deploying its AI-POWR machine learning platform in its clinical program to tackle non-alcoholic...

November 10, 2020

Features

Micron developing microneedle technology for self-administration of vaccines and therapeutics

Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics.

November 3, 2020

Cyclacel translating cancer biology into potential medicines

Entasis Therapeutics targeting critical pathogens with precision antibiotics

Varsha Rao talks up Nurx convenient and affordable care for sensitive health needs

KA Imaging Reveal device a game changer in reinventing X-ray with dual energy

Petros Pharma looking to pursue OTC status for its Stendra erectile dysfunction therapy

Kezar Life Sciences harnessing master regulators of cellular functions to tackle disease

111’s next-gen S2B2C model is transforming China’s legacy healthcare system

Keith Sullivan discusses turnaround plan for Neuronetics

Achieve Life Sciences in pivotal trial with cytisinicline for new smoking cessation and nicotine addiction treatment

VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder

ARSTAT developing portfolio of transformational products for women’s health

Lineage Cell Therapeutics readies milestone-rich 2021 in 3 clinical programs

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

Tarsus Pharma developing first treatment for Demodex blepharitis, an ocular condition

Sernova in clinical development for functional cure of Type 1 Insulin-dependent diabetes

Ripple Therapeutics lead candidate attracts strategic investment and licensing partner

Plus Therapeutics targeting potent radiotherapy directly against glioblastoma

Genelux advancing oncolytic vaccinia virus into pivotal ovarian cancer trial in 2021

Izotropic Breast CT Imaging System targeting earlier cancer detection

Kintara Therapeutics readies two late-stage cancer drug candidates

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

Micron developing microneedle technology for self-administration of vaccines and therapeutics

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter